The venture capital firm Forbion has announced a large financing for one of its portfolio companies, NewAmsterdam Pharma BV, which is planning Phase 3 development of a cholesterol lowering drug for patients who aren’t well controlled on statins. The oversubscribed €160 million Series A round was led by Forbion and co-led by Morningside Ventures and Ascendant BioCapital.
